Dec 12, 2024 08:16AM

Dec 11, 2024 07:32AM

Dec 11, 2024 07:30AM

Dec 10, 2024 07:30AM

Dec 6, 2024 08:34AM

Nov 19, 2024 07:00AM

Nov 4, 2024 08:00AM AIM ImmunoTech Files Definitive Proxy Statement and Sends Letter to Shareholders

Nov 16, 2023 08:45AM

Nov 16, 2023 08:45AM

Nov 6, 2023 09:25AM

Mar 16, 2023 08:45AM

Mar 16, 2023 08:45AM

Mar 8, 2023 08:45AM

Mar 8, 2023 08:45AM AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease

Mar 6, 2023 08:45AM

Mar 6, 2023 08:45AM

Feb 17, 2023 08:55AM

Nov 15, 2022 07:00AM

Nov 9, 2022 09:00AM

Nov 2, 2022 07:14AM

Nov 2, 2022 07:05AM AIM ImmunoTech Receives Orphan Drug Designation for Ampligen (rintatolimod) for the Treatment of Ebola Virus Disease

Nov 1, 2022 01:59PM

Oct 26, 2022 05:13PM

Oct 26, 2022 05:12PM

Oct 12, 2022 08:46AM

Oct 12, 2022 08:45AM

Sep 21, 2022 08:45AM

Sep 19, 2022 08:05AM AIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to Shareholders

Aug 18, 2022 09:05AM

Aug 15, 2022 08:05AM

Jul 28, 2022 09:10AM

Jul 28, 2022 09:10AM

Jul 21, 2022 12:26PM

Jun 13, 2022 08:06AM

Jun 13, 2022 08:05AM AIM ImmunoTech Bolsters Intellectual Property Portfolio for Ampligen® with Issuance of New Netherlands Utility Patent Covering Ampligen® and other AIM Developed dsRNA Products for Use in COVID-19 Tr

May 18, 2022 08:06AM

May 18, 2022 08:00AM

May 16, 2022 07:05AM

Apr 12, 2022 07:49AM

Apr 12, 2022 07:47AM

Mar 31, 2022 04:05PM

Mar 16, 2022 07:07AM AIM ImmunoTech (AIM) Granted FDA IND Clearance to Advance its Phase 2 Study of Ampligen for the Treatment of Locally Advanced Pancreatic Cancer

Mar 16, 2022 07:05AM

Mar 8, 2022 02:00PM

Mar 8, 2022 01:59PM

Nov 16, 2021 07:00AM

Oct 19, 2021 07:41AM

Oct 19, 2021 07:25AM

Oct 6, 2021 07:25AM AIM ImmunoTech (AIM) Publishes Phase 1 Clinical Study Data Supporting the Safety of Ampligen as an Intranasal Therapy

Oct 6, 2021 07:25AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All